CAMP4 Therapeutics Corporation Forward Contract Indexed to Issuer's Equity, Settlement Alternatives, Cash, at Fair Value
CAMP4 Therapeutics Corporation (CAMP) had Forward Contract Indexed to Issuer's Equity, Settlement Alternatives, Cash, at Fair Value of $50.10 million as of 2025-09-11, per its 10-Q filed 2026-05-07.
Financial Statements › Notes › Other Liabilities
us-gaap:ForwardContractIndexedToIssuersEquitySettlementAlternativesCashAtFairValue · last filed 2026-08-13
- 2025-09-11: Forward Contract Indexed to Issuer's Equity, Settlement Alternatives, Cash, at Fair Value $50.10M.
- 2025-09-09: Forward Contract Indexed to Issuer's Equity, Settlement Alternatives, Cash, at Fair Value $50.10M.
| Period end | Forward Contract Indexed to Issuer's Equity, Settlement Alternatives, Cash, at Fair Value |
|---|---|
| 2025-09-11 | $50.10M 10-Q · filed 2026-05-07 |
| 2025-09-09 | $50.10M 10-Q · filed 2026-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |